## Denise Hilfiker-Kleiner

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/509970/denise-hilfiker-kleiner-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166 105 11,250 57 h-index g-index citations papers 181 13,497 5.9 9.4 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
166	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart <i>Cardiovascular Research</i> , <b>2022</b> ,	9.9	3
165	Loss of vascular endothelial notch signaling promotes spontaneous formation of tertiary lymphoid structures <i>Nature Communications</i> , <b>2022</b> , 13, 2022	17.4	1
164	High prevalence of reduced fertility and use of assisted reproductive technology in a German cohort of patients with peripartum cardiomyopathy <i>Clinical Research in Cardiology</i> , <b>2022</b> , 1	6.1	O
163	Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals. <i>Journal of Nuclear Cardiology</i> , <b>2021</b> , 28, 1636-1645	2.1	15
162	Anthracycline-free tumor elimination in mice leads tolfunctional and molecular cardiac recovery from cancer-induced alterations in contrast to long-lasting doxorubicin treatment effects. <i>Basic Research in Cardiology</i> , <b>2021</b> , 116, 61	11.8	2
161	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy.  European Journal of Heart Failure, 2021, 23, 527-540	12.3	10
160	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. <i>Circulation</i> , <b>2021</b> , 143, 1852-1862	16.7	11
159	Perhexiline treatment improves toxic effects of Endrenergic receptor stimulation in experimental peripartum cardiomyopathy. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3375-3381	3.7	1
158	Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00371	4.2	1
157	ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e006898	7.6	O
156	Peripartum cardiomyopathy: from genetics to management. European Heart Journal, <b>2021</b> , 42, 3094-31	<b>03</b> .5	4
155	What needs to be known about longer-term management and prognosis? 2021, 45-65		
154	Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. <i>PLoS ONE</i> , <b>2021</b> , 16, e0255335	3.7	13
153	Etiology and pathophysiology <b>2021</b> , 1-11		
152	Assessment of major mental disorders in a German peripartum cardiomyopathy cohort. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 4394	3.7	8
151	Human iPSC-Derived Cardiomyocytes of Peripartum Patients With Cardiomyopathy Reveal Aberrant Regulation of Lipid Metabolism. <i>Circulation</i> , <b>2020</b> , 142, 2288-2291	16.7	3
150	Effects of six month personalized endurance training on work ability in middle-aged sedentary women: a secondary analysis of a randomized controlled trial. <i>Journal of Occupational Medicine and Toxicology</i> , <b>2020</b> , 15, 8	2.7	1

149	Onkologische Kardiologie. <i>Kardiologe</i> , <b>2020</b> , 14, 267-293	0.6	1
148	Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 1197-1222	6.1	27
147	Employers With Metabolic Syndrome and Increased Depression/Anxiety Severity Profit Most From Structured Exercise Intervention for Work Ability and Quality of Life. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 562	5	5
146	Common genetic predisposition for heart failure and cancer. <i>Herz</i> , <b>2020</b> , 45, 632-636	2.6	5
145	Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markers. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 512-522	3.7	9
144	miR-21 and NT-proBNP Correlate with Echocardiographic Parameters of Atrial Dysfunction and Predict Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	10
143	Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation. <i>PLoS Biology</i> , <b>2020</b> , 18, e3000739	9.7	1
142	In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. <i>Cardiovascular Research</i> , <b>2020</b> , 116, 1875-1886	9.9	10
141	Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages. <i>Basic Research in Cardiology</i> , <b>2020</b> , 115, 62	11.8	26
140	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , <b>2020</b> , 41, 3787-3797	9.5	35
139	Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2020</b> , 9, 173-1	1 <b>82</b> <sup>3</sup>	22
138	Peripartum cardiomyopathy: basic mechanisms and hope for new therapies. <i>Cardiovascular Research</i> , <b>2020</b> , 116, 520-531	9.9	13
137	Modulation of cardiac AKT and STAT3 signalling in preclinical cancer models and their impact on the heart. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2020</b> , 1867, 118519	4.9	7
136	Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation <b>2020</b> , 18, e3000739		
135	Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation <b>2020</b> , 18, e3000739		
134	Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation <b>2020</b> , 18, e3000739		
133	Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation <b>2020</b> , 18, e3000739		
132	Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation <b>2020</b> , 18, e3000739		

Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation **2020**, 18, e3000739

130	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 827-843	12.3	107
129	Telemonitoring-supported exercise training, metabolic syndrome severity, and work ability in company employees: a randomised controlled trial. <i>Lancet Public Health, The</i> , <b>2019</b> , 4, e343-e352	22.4	21
128	Letter by Hilfiker-Kleiner et al Regarding Article, "Modeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytes". <i>Circulation</i> , <b>2019</b> , 139, e990-e991	16.7	
127	Effects of personalized endurance training on cellular age and vascular function in middle-aged sedentary women. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 1903-1906	3.9	5
126	Comorbidities and Co-Existing Conditions in Heart Failure Around Pregnancy. <i>Cardiovascular Medicine</i> , <b>2019</b> , 63-70	0.1	
125	Future cardiovascular risk prediction in women with pregnancy complications: the HUNT is on. <i>European Heart Journal</i> , <b>2019</b> , 40, 1121-1123	9.5	3
124	Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 290-297	6.1	17
123	Data on left ventricular expression of STAT3 and AKT in transgenic mouse models with B16F10 melanoma. <i>Data in Brief</i> , <b>2019</b> , 26, 104508	1.2	1
122	Fluoxetine induces glucose uptake and modifies glucose transporter palmitoylation in human peripheral blood mononuclear cells. <i>Expert Opinion on Therapeutic Targets</i> , <b>2019</b> , 23, 883-891	6.4	9
121	Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1534-1542	12.3	29
120	Late onset heart failure after childhood chemotherapy. European Heart Journal, 2019, 40, 798-800	9.5	14
119	Breastfeeding in Patients With Heart[Failure: Lack of Evidence and Consensus. <i>JACC Basic To Translational Science</i> , <b>2019</b> , 4, 866-867	8.7	0
118	Increased Cancer Prevalence in Peripartum Cardiomyopathy. <i>JACC: CardioOncology</i> , <b>2019</b> , 1, 196-205	3.8	17
117	Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. <i>PLoS ONE</i> , <b>2019</b> , 14, e0225977	3.7	4
116	Sex differences in heart failure. <i>European Heart Journal</i> , <b>2019</b> , 40, 3859-3868c	9.5	159
115	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 1313-1323	10.7	6
114	Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing. <i>Hypertension</i> , <b>2019</b> , 73, 102-111	8.5	18

113	Cardiology and cardiovascular research in Germany: 5 Dyears of gender demographics. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 218-220	6.1	2
112	Electrophysiological abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients. <i>Journal of Cellular and Molecular Medicine</i> , <b>2019</b> , 23, 2125-2135	5.6	23
111	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644	9.5	51
110	Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of	12.3	62
109	A positive feedback loop between IL-1 DLPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages. <i>Vascular Pharmacology</i> , <b>2018</b> , 103-105, 16-28	5.9	39
108	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 445-459	12.3	67
107	Regulation and function of endothelial glycocalyx layer in vascular diseases. <i>Vascular Pharmacology</i> , <b>2018</b> , 100, 26-33	5.9	96
106	Reply to Bromocriptine for the treatment of peripartum cardiomyopathy: comparison of outcome with a nationwide Danish cohortP. <i>European Heart Journal</i> , <b>2018</b> , 39, 3478	9.5	O
105	Optimized Induction of Mitochondrial Apoptosis By Combination Therapies with Venetoclax for Chemotherapy-Free Treatment of BCR-ABL+ Acute Lymphoblastic Leukemia in Preclinical Models. <i>Blood</i> , <b>2018</b> , 132, 4025-4025	2.2	
104	Pregnancy and Heart Disease: Pregnancy-Associated Hypertension and Peripartum Cardiomyopathy. <i>Current Problems in Cardiology</i> , <b>2018</b> , 43, 364-388	17.1	9
103	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 216-227	12.3	59
102	Cardiomyopathies and Congenital Heart Disease in Pregnancy. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2018</b> , 78, 1256-1261	2	2
101	miR-125b regulates chemotaxis and survival of bone marrow derived granulocytes in vitro and in vivo. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204942	3.7	3
100	Bromocriptine for the Treatment of Peripartum Cardiomyopathy. <i>Cardiac Failure Review</i> , <b>2018</b> , 4, 46-49	4.2	9
99	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. <i>Cardiovascular Research</i> , <b>2018</b> , 114, 1287-1303	9.9	57
98	Olanzapine and aripiprazole differentially affect glucose uptake and energy metabolism in human mononuclear blood cells. <i>Journal of Psychiatric Research</i> , <b>2017</b> , 88, 18-27	5.2	8
97	Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy. <i>Cardiovascular Research</i> , <b>2017</b> , 113, 598-608	9.9	15
96	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. European Journal of Heart Failure,	12.3	114

95	Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1723-1728	12.3	59
94	Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. <i>Clinical Research in Cardiology</i> , <b>2017</b> , 106, 582-589	6.1	43
93	Myofilament Remodeling and Function Is More Impaired in Peripartum Cardiomyopathy Compared with Dilated Cardiomyopathy and Ischemic Heart Disease. <i>American Journal of Pathology</i> , <b>2017</b> , 187, 2645-2658	5.8	16
92	Low STAT3 expression sensitizes to toxic effects of Edrenergic receptor stimulation in peripartum cardiomyopathy. <i>European Heart Journal</i> , <b>2017</b> , 38, 349-361	9.5	63
91	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. <i>European Heart Journal</i> , <b>2017</b> , 38, 2671-2679	9.5	160
90	Complete recovery of fulminant peripartum cardiomyopathy on mechanical circulatory support combined with high-dose bromocriptine therapy. ESC Heart Failure, 2017, 4, 641-644	3.7	12
89	cUMP hydrolysis by PDE3A. <i>Naunyn-Schmiedebergfs Archives of Pharmacology</i> , <b>2017</b> , 390, 269-280	3.4	6
88	Dnmt3a-mediated inhibition of Wnt in cardiac progenitor cells improves differentiation and remote remodeling after infarction. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	8
87	Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	22
86	Cardiomyopathies in Women <b>2017</b> , 127-139		
86 85	Cardiomyopathies in Women <b>2017</b> , 127-139  MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. <i>Circulation</i> , <b>2016</b> , 134, 1973-1990	16.7	32
		16.7	32
85	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. <i>Circulation</i> , <b>2016</b> , 134, 1973-1990  Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on	,	
8 <sub>5</sub>	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. <i>Circulation</i> , <b>2016</b> , 134, 1973-1990  Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1096-105  Comparison of the American PPCM Registry Data With International Registries. <i>Journal of the</i>	12.3	
85 84 83	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. <i>Circulation</i> , <b>2016</b> , 134, 1973-1990  Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1096-105  Comparison of the American PPCM Registry Data With International Registries. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 733-734  Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. <i>New England Journal</i>	12.3	104
85 84 83 82	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. <i>Circulation</i> , <b>2016</b> , 134, 1973-1990  Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1096-105  Comparison of the American PPCM Registry Data With International Registries. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 733-734  Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 233-41  In vitro maturation of large-scale cardiac patches based on a perfusable starter matrix by cyclic	12.3 15.1 59.2	104
85 84 83 82 81	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. <i>Circulation</i> , <b>2016</b> , 134, 1973-1990  Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1096-105  Comparison of the American PPCM Registry[Data With International Registries. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 733-734  Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 233-41  In vitro maturation of large-scale cardiac patches based on a perfusable starter matrix by cyclic mechanical stimulation. <i>Acta Biomaterialia</i> , <b>2016</b> , 30, 177-187  Stable Silencing of RUNX1/ETO Induces Expression of a Shortened PU.1 Variant in t(8;21) Kasumi	12.3 15.1 59.2	104

77	Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry. <i>International Journal of Cardiology</i> , <b>2016</b> , 216, 165-7	3.2	25
76	Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. <i>Cardiovascular Research</i> , <b>2015</b> , 106, 365-74	9.9	63
75	Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. <i>Nature Medicine</i> , <b>2015</b> , 21, 601-9	50.5	84
74	Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. <i>Basic Research in Cardiology</i> , <b>2015</b> , 110, 60	11.8	36
73	Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. <i>ESC Heart Failure</i> , <b>2015</b> , 2, 139-149	3.7	43
72	Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. <i>Clinical Research in Cardiology</i> , <b>2015</b> , 104, 911-7	6.1	44
71	Peripartum cardiomyopathy: current management and future perspectives. <i>European Heart Journal</i> , <b>2015</b> , 36, 1090-7	9.5	143
70	Schwangerschaftsassoziierte Kardiomyopathie <b>2015</b> , 1-11		
69	Schwangerschaftsassoziierte Kardiomyopathie <b>2015</b> , 1-13		
68	Pathophysiology and epidemiology of peripartum cardiomyopathy. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 364-70	14.8	147
68 67		14.8 5.8	147 6 <sub>7</sub>
	2014, 11, 364-70  oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor	5.8	"
67	oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2014</b> , 66, 72-82	5.8	67
67 66	oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2014</b> , 66, 72-82  Improvement of biological age by physical activity. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 1187-Expression of fibulin-6 in failing hearts and its role for cardiac fibroblast migration. <i>Cardiovascular</i>	5.8 93.2	67
67 66 65	oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2014</b> , 66, 72-82  Improvement of biological age by physical activity. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 1187-Expression of fibulin-6 in failing hearts and its role for cardiac fibroblast migration. <i>Cardiovascular Research</i> , <b>2014</b> , 103, 509-20	5.8 93.2 9.9	67 23 22
67 66 65	oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2014</b> , 66, 72-82  Improvement of biological age by physical activity. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 1187-Expression of fibulin-6 in failing hearts and its role for cardiac fibroblast migration. <i>Cardiovascular Research</i> , <b>2014</b> , 103, 509-20  Small molecule-mediated refolding and activation of myosin motor function. <i>ELife</i> , <b>2014</b> , 3, e01603  STAT3, a key regulator of cell-to-cell communication in the heart. <i>Cardiovascular Research</i> , <b>2014</b> ,	5.8 93.2 9.9	67 23 22 36
67 66 65 64 63	oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2014</b> , 66, 72-82  Improvement of biological age by physical activity. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 1187-  Expression of fibulin-6 in failing hearts and its role for cardiac fibroblast migration. <i>Cardiovascular Research</i> , <b>2014</b> , 103, 509-20  Small molecule-mediated refolding and activation of myosin motor function. <i>ELife</i> , <b>2014</b> , 3, e01603  STAT3, a key regulator of cell-to-cell communication in the heart. <i>Cardiovascular Research</i> , <b>2014</b> , 102, 281-9  Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. <i>European Journal of Heart Failure</i> , <b>2014</b> ,	5.8 93.2 9.9 8.9	67 23 22 36 71

59	EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 583-91	12.3	80
58	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. <i>European Heart Journal</i> , <b>2014</b> , 35, 2165-73	9.5	117
57	Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 494-508	12.3	71
56	Cardiovascular disorders in pregnancy: diagnosis and management. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2013</b> , 27, 821-34	4.6	14
55	Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. <i>Basic Research in Cardiology</i> , <b>2013</b> , 108, 366	11.8	198
54	Article Commentary: Acute Heart Failure: Is it Peripartum Cardiomyopathy or Not?. <i>Obstetric Medicine</i> , <b>2013</b> , 6, 42-44	1.5	
53	Peripartum cardiomyopathy: update 2012. Current Opinion in Critical Care, 2013, 19, 397-403	3.5	10
52	Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. <i>Heart</i> , <b>2013</b> , 99, 308-13	5.1	102
51	MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 2143-54	15.9	315
50	Mir~17-92 Identifies BCL2 As a Therapeutic Target In BCR-ABL Positive B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 835-835	2.2	
50		2.2	1
	Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 835-835	2.2	1 348
49	Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 835-835  The STAT3 Pathway and Downstream Mechanisms in Cardiac Remodeling: Friend or Foe <b>2013</b> , 347-364		2
49 48	Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 835-835  The STAT3 Pathway and Downstream Mechanisms in Cardiac Remodeling: Friend or Foe <b>2013</b> , 347-364  Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. <i>Nature</i> , <b>2012</b> , 485, 333-8  16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. <i>Current Heart Failure Reports</i> ,	50.4	348
49 48 47	Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 835-835  The STAT3 Pathway and Downstream Mechanisms in Cardiac Remodeling: Friend or Foe <b>2013</b> , 347-364  Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. <i>Nature</i> , <b>2012</b> , 485, 333-8  16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. <i>Current Heart Failure Reports</i> , <b>2012</b> , 9, 174-82  Protective Function of STAT3 in CVB3-Induced Myocarditis. <i>Cardiology Research and Practice</i> , <b>2012</b> ,	50.4	348
49 48 47 46	Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 835-835  The STAT3 Pathway and Downstream Mechanisms in Cardiac Remodeling: Friend or Foe <b>2013</b> , 347-364  Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. <i>Nature</i> , <b>2012</b> , 485, 333-8  16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. <i>Current Heart Failure Reports</i> , <b>2012</b> , 9, 174-82  Protective Function of STAT3 in CVB3-Induced Myocarditis. <i>Cardiology Research and Practice</i> , <b>2012</b> , 2012, 437623	50.4	348 35
49 48 47 46 45	Lymphoblastic Leukemia. <i>Blood</i> , <b>2013</b> , 122, 835-835  The STAT3 Pathway and Downstream Mechanisms in Cardiac Remodeling: Friend or Foe <b>2013</b> , 347-364  Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. <i>Nature</i> , <b>2012</b> , 485, 333-8  16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. <i>Current Heart Failure Reports</i> , <b>2012</b> , 9, 174-82  Protective Function of STAT3 in CVB3-Induced Myocarditis. <i>Cardiology Research and Practice</i> , <b>2012</b> , 2012, 437623  STAT3 regulation of and by microRNAs in development and disease. <i>Jak-stat</i> , <b>2012</b> , 1, 143-50  Circulating microparticles as indicators of peripartum cardiomyopathy. <i>European Heart Journal</i> ,	50.4 2.8 1.9	348 35 15 30

## (2008-2011)

41	Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies. <i>Cell Stem Cell</i> , <b>2011</b> , 9, 131-43	18	60
40	ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2011</b> , 32, 3147-97	9.5	1167
39	STAT3 and cardiac remodeling. <i>Heart Failure Reviews</i> , <b>2011</b> , 16, 35-47	5	74
38	Left bundle branch block during pregnancy as a sign of imminent peripartum cardiomyopathy. <i>European Heart Journal</i> , <b>2011</b> , 32, 1076	9.5	8
37	Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. <i>European Heart Journal</i> , <b>2011</b> , 32, 1287-97	9.5	99
36	Prolactin: a new therapeutic target in peripartum cardiomyopathy. <i>Heart</i> , <b>2010</b> , 96, 1352-7	5.1	35
35	Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. <i>Circulation</i> , <b>2010</b> , 122, 145-55	16.7	120
34	Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. <i>Journal of Medical Case Reports</i> , <b>2010</b> , 4, 80	1.2	23
33	Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. <i>Circulation</i> , <b>2010</b> , 121, 1465-73	16.7	319
32	Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> ,	12.3	569
31	Peripartum Cardiomyopathy: Role of STAT-3 and Reactive Oxygen Species <b>2010</b> , 317-337		
30	Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiology, 2009, 5, 175-89	1.3	35
29	The myocardial JAK/STAT pathway: from protection to failure 2008, 120, 172-85		259
28	Peripartum cardiomyopathy: recent insights in its pathophysiology. <i>Trends in Cardiovascular Medicine</i> , <b>2008</b> , 18, 173-9	6.9	71
27	Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. <i>Circulation Research</i> , <b>2008</b> , 102, 131-5	15.7	225
26	Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 861-8	12.3	132
25	Disease-modifying mutations in familial hypertrophic cardiomyopathy: complexity from simplicity. <i>Circulation</i> , <b>2008</b> , 117, 1775-7	16.7	10
24	Management of peripartum cardiomyopathy. Current Heart Failure Reports, 2008, 5, 238-44	2.8	11

23	Peripartum cardiomyopathya new treatment option by inhibition of prolactin secretion. <i>American Journal of Obstetrics and Gynecology</i> , <b>2008</b> , 199, e5-6	6.4	49
22	Postpartum cardiomyopathy: a cardiac emergency for gynecologists, general practitioners, internists, pulmonologists, and cardiologists. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2008</b> , 105, 751-6	2.5	12
21	Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 2354-5	15.1	83
20	Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. <i>Basic Research in Cardiology</i> , <b>2007</b> , 102, 393-411	11.8	132
19	MYOCARDIAL AUTOANTIBODIES AND THEIR CLINICAL SIGNIFICANCE <b>2007</b> , 355-365		1
18	A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. <i>Cell</i> , <b>2007</b> , 128, 589-600	56.2	586
17	Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. <i>European Heart Journal</i> , <b>2006</b> , 27, 441-6	9.5	216
16	JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity. <i>Cardiovascular Research</i> , <b>2006</b> , 71, 108-17	9.9	27
15	Preclinical testing of tissue-engineered heart valves re-endothelialized under simulated physiological conditions. <i>Circulation</i> , <b>2006</b> , 114, I559-65	16.7	98
14	Molecular Mechanisms in Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, A56-A6	6615.1	97
14	Molecular Mechanisms in Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, A56-A66 STAT3-mediated activation of myocardial capillary growth. <i>Trends in Cardiovascular Medicine</i> , <b>2005</b> , 15, 152-7	6.9	97 53
, i	STAT3-mediated activation of myocardial capillary growth. <i>Trends in Cardiovascular Medicine</i> , <b>2005</b> ,		
13	STAT3-mediated activation of myocardial capillary growth. <i>Trends in Cardiovascular Medicine</i> , <b>2005</b> , 15, 152-7		53
13	STAT3-mediated activation of myocardial capillary growth. <i>Trends in Cardiovascular Medicine</i> , <b>2005</b> , 15, 152-7  Many good reasons to have STAT3 in the heart <b>2005</b> , 107, 131-7  Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and	6.9	53
13 12 11	STAT3-mediated activation of myocardial capillary growth. <i>Trends in Cardiovascular Medicine</i> , <b>2005</b> , 15, 152-7  Many good reasons to have STAT3 in the heart <b>2005</b> , 107, 131-7  Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart. <i>Circulation</i> , <b>2005</b> , 112, 1470-7  Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy	6.9	53 86 56
13 12 11	STAT3-mediated activation of myocardial capillary growth. <i>Trends in Cardiovascular Medicine</i> , <b>2005</b> , 15, 152-7  Many good reasons to have STAT3 in the heart <b>2005</b> , 107, 131-7  Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart. <i>Circulation</i> , <b>2005</b> , 112, 1470-7  Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon. <i>Circulation Research</i> , <b>2005</b> , 96, 748-55  Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. <i>Circulation</i>	6.9 16.7	<ul><li>53</li><li>86</li><li>56</li><li>69</li></ul>
13 12 11 10 9	STAT3-mediated activation of myocardial capillary growth. <i>Trends in Cardiovascular Medicine</i> , 2005, 15, 152-7  Many good reasons to have STAT3 in the heart 2005, 107, 131-7  Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart. <i>Circulation</i> , 2005, 112, 1470-7  Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon. <i>Circulation Research</i> , 2005, 96, 748-55  Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. <i>Circulation Research</i> , 2004, 95, 187-95  Regulation of proangiogenic factor CCN1 in cardiac muscle: impact of ischemia, pressure overload,	6.9 16.7 15.7	<ul><li>53</li><li>86</li><li>56</li><li>69</li><li>316</li></ul>

## LIST OF PUBLICATIONS

5	Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. <i>FASEB Journal</i> , <b>2003</b> , 17, 2118-20	0.9	92
4	Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. <i>Circulation</i> , <b>2002</b> , 106, 254-60	16.7	90
3	TNFalpha decreases alphaMHC expression by a NO mediated pathway: role of E-box transcription factors for cardiomyocyte specific gene regulation. <i>Cardiovascular Research</i> , <b>2002</b> , 53, 460-9	9.9	10
2	Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. <i>Circulation Research</i> , <b>2000</b> , 87, 1195-201	15.7	230
1	Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. <i>Circulation</i> , <b>2000</b> , 101, 1372-8	16.7	551